InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $1.775 0.055 (3.01%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,310 Appendix 4C - quarterly 31 Jan 2013 6:01PM $5.980 $1.775 fallen by 70.32%
$2,310 FDA CLEARS PHASE 2 CLINICAL TRIAL FOR RHEUMATOID ARTHRITIS 30 Jan 2013 10:31AM $5.800 $1.775 fallen by 69.40%
$2,310 Positive Results in Phase 2 Lumbar Spinal Fusion Trial 11 Jan 2013 9:14AM $5.740 $1.775 fallen by 69.08%
$2,310 Mesoblast Corporate Overview - CEO Message to AGM 29 Nov 2012 2:27PM $5.980 $1.775 fallen by 70.32%
$2,310 Key Manufacturing Agreement with FDA for Phase 3 Trials 20 Nov 2012 9:32AM $5.250 $1.775 fallen by 66.19%
$2,310 Price Query 15 Nov 2012 2:21PM $5.120 $1.775 fallen by 65.33%
$2,310 Appendix 4C - quarterly 31 Oct 2012 5:33PM $5.770 $1.775 fallen by 69.24%
$2,310 Preliminary Final Report 22 Aug 2012 9:55AM $6.450 $1.775 fallen by 72.48%
$2,310 Appendix 4C - quarterly 31 Jul 2012 4:31PM $6.290 $1.775 fallen by 71.78%
$2,310 Rheumatoid Arthritis New Major Clinical Target for MSB 24 Jul 2012 9:58AM $5.900 $1.775 fallen by 69.92%
$2,310 Response to ASXPrice Query 18 Jun 2012 10:00AM $5.930 $1.775 fallen by 70.07%
$2,310 MSB Provides Corporate Strategy For Neurologic Product 8 Jun 2012 10:04AM $6.350 $1.775 fallen by 72.05%
$2,310 Appendix 4C - quarterly 30 Apr 2012 4:34PM $7.070 $1.775 fallen by 74.89%
$2,310 Intervertebral Disc Repair Phase 2 Trial Update 17 Apr 2012 10:04AM $7.250 $1.775 fallen by 75.52%
$2,310 Half Yearly Report and Accounts 27 Feb 2012 10:59AM $7.800 $1.775 fallen by 77.24%
$2,310 FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes 31 Jan 2012 11:09AM $6.450 $1.775 fallen by 72.48%
$2,310 Appendix 4C - quarterly 12 Jan 2012 8:25PM $6.550 $1.775 fallen by 72.90%
$2,310 Positive Outcome From FDA Meeting For Diabetes Program 22 Nov 2011 10:00AM $6.950 $1.775 fallen by 74.46%
$2,310 Positive Heart Failure Trial Results Presented to AHA 15 Nov 2011 8:25AM $7.750 $1.775 fallen by 77.10%
$2,310 Positive Results Using Adult Stem Cells for Type 2 Diabetes 10 Nov 2011 8:27AM $7.500 $1.775 fallen by 76.33%
$2,310 Appendix 4C - quarterly 31 Oct 2011 5:22PM $8.050 $1.775 fallen by 77.95%
$2,310 Response to ASX Price Query Letter 28 Oct 2011 3:40PM $8.450 $1.775 fallen by 78.99%
$2,310 Clearance for First Phase 2 Clinical Trial for Eye Diseases 24 Oct 2011 9:34AM $9.990 $1.775 fallen by 82.23%
$2,310 Licensing Executives Society Deals of Distinction Award 20 Oct 2011 10:21AM $9.650 $1.775 fallen by 81.61%
$2,310 MSB and Lonza form strategic global manufacturing alliance 27 Sep 2011 8:27AM $7.800 $1.775 fallen by 77.24%

1026 - 1050 of 1198 results

Page 42 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.